The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Selecting a therapy for patients with ITP and additional comorbidities
In this video, Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, briefly discusses treatment selection in patients with immune thrombocytopenia (ITP) and additional comorbidities, highlighting the importance of shared decision-making and considering how a therapy’s side-effect profile may overlap with underlying comorbidities. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This goes back to the way that we should all select agents in ITP, which is shared decision-making with an understanding of the patient’s underlying comorbidities. So, you know, if somebody has ongoing comorbidities that are relevant to a certain drug, like, for example, antiphospholipid antibody syndrome, then, you know some people would think twice before starting a thrombopoietin receptor agonist, particularly if they have a strong history of thrombosis...
This goes back to the way that we should all select agents in ITP, which is shared decision-making with an understanding of the patient’s underlying comorbidities. So, you know, if somebody has ongoing comorbidities that are relevant to a certain drug, like, for example, antiphospholipid antibody syndrome, then, you know some people would think twice before starting a thrombopoietin receptor agonist, particularly if they have a strong history of thrombosis. Some patients with antiphospholipid antibody syndrome do just fine on a thrombopoietin receptor agonist. So I think that it’s always a measure of relative risk and benefit, and trying, obviously, to match up a drug’s potential, you know, trying to avoid a drug’s potential toxicity profile overlapping with what’s going on in that patient’s medical history as much as possible. But beyond that, you know, it’s a patient-by-patient, you know, art.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
